Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights mixed signals: strong bookings, backlog, and growth in some segments, but negative free cash flow and rising debt. The Q&A revealed unclear responses on Healthcare engagement trends and AI growth specifics, suggesting potential concerns. Despite positive elements like record RBR growth and a strong buying environment in Education, uncertainties around Digital performance and leverage ratios suggest a neutral stock price movement. The market cap indicates moderate volatility, aligning with a neutral sentiment.
Revenues Before Reimbursable Expenses (RBR) $443.7 million in Q1 2026, up 12.1% from $395.7 million in Q1 2025. Growth was driven by increases across all three operating segments.
Net Income $23.2 million in Q1 2026, down from $24.5 million in Q1 2025. The decline was due to a higher effective tax rate in Q1 2026.
Adjusted EBITDA $50.6 million in Q1 2026 (11.4% of RBR), up from $41.5 million in Q1 2025 (10.5% of RBR). The increase was driven by higher segment operating income across all three segments.
Healthcare Segment RBR $225.2 million in Q1 2026, up 13.5% from Q1 2025. Growth was driven by strong demand for performance improvement, revenue cycle managed services, financial advisory, and strategy offerings, as well as $7.3 million from acquisitions.
Education Segment RBR $127.5 million in Q1 2026, up 3.8% from Q1 2025. Growth was driven by strong demand for digital offerings and a $600,000 contribution from acquisitions.
Commercial Segment RBR $91 million in Q1 2026, up 22.3% from Q1 2025. Growth was driven by increased demand for financial advisory and strategy offerings, including $11 million from acquisitions.
Operating Income Margin - Healthcare Segment 28.4% in both Q1 2026 and Q1 2025, remaining flat.
Operating Income Margin - Education Segment 21.6% in Q1 2026, up from 18.8% in Q1 2025. The increase was due to decreases in compensation costs, practice administration, and meeting expenses.
Operating Income Margin - Commercial Segment 16.4% in Q1 2026, up from 15.2% in Q1 2025. The increase was driven by decreases in contractor expenses and salaries for support personnel, as well as revenue growth outpacing performance bonus expenses.
Cash Flow Used in Operations $162.2 million in Q1 2026, compared to $106.8 million in Q1 2025. The increase was due to annual incentive payments.
Free Cash Flow Negative $174 million in Q1 2026, reflecting $11.9 million in capital expenditures.
Days Sales Outstanding (DSO) 82 days in Q1 2026, up from 79 days in Q1 2025 and 73 days in Q4 2025. The increase was due to larger Healthcare projects with performance-based fee elements.
Total Debt $856 million as of March 31, 2026, up from Q4 2025 due to annual cash bonus payments and share repurchases.
Leverage Ratio 3.1x adjusted EBITDA as of March 31, 2026, compared to 2.2x as of March 31, 2025. The increase reflects seasonal high leverage due to annual bonus payouts.
AI capabilities in Healthcare: Rapid expansion and integration of AI capabilities across Healthcare offerings to address challenges and opportunities in clinical, administrative, and financial workflows.
AI capabilities in Education: Higher education institutions are increasingly leveraging AI to modernize operating models, core administrative workflows, and academic offerings.
AI capabilities in Commercial: Companies are accelerating the adoption of AI-enabled data-driven operating models to improve agility, productivity, and decision-making.
Healthcare segment growth: Healthcare segment RBR grew 14% year-over-year, driven by strong demand for performance improvement, revenue cycle managed services, financial advisory, and strategy offerings.
Education segment growth: Education segment RBR grew 4% year-over-year, driven by strong demand for digital offerings.
Commercial segment growth: Commercial segment RBR grew 22% year-over-year, driven by demand for financial advisory and strategy offerings.
Margin expansion: Disciplined execution led to margin expansion across all segments, with adjusted EBITDA margin increasing to 11.4% from 10.5% year-over-year.
Capital allocation: Repurchased 1.1 million shares (6.5% of outstanding shares) and maintained a leverage ratio of 3.1x adjusted EBITDA.
AI investment: Substantial increase in AI investments to deploy capabilities across offerings and operations, positioning for future growth and margin expansion.
Acquisitions: Incremental RBR growth from acquisitions such as Treliant, Wilson Perumal, and Eclipse Insights.
Healthcare Segment: Healthcare providers face competitive and regulatory pressures impacting financial performance. Challenges include declining reimbursements, rising operational costs, and labor shortages. Rapid technological advancements require providers to develop and execute AI strategies to adapt to changes.
Education Segment: Higher education institutions are experiencing uneven domestic demand and a significant decline in international students. They face rising operating costs, funding declines, regulatory scrutiny, and erosion of public confidence in traditional degrees. These issues challenge financial sustainability and operational efficiency.
Commercial Segment: Commercial industries are dealing with persistent cost inflation, global supply chain realignment, geopolitical and regulatory uncertainty, and evolving customer and employee expectations. These factors increase operational complexity and demand for AI-enabled solutions.
Financial Performance: The company experienced a decline in net income as a percentage of total revenues due to a higher effective tax rate. Additionally, cash flow used in operations increased significantly, and the leverage ratio rose, reflecting higher debt levels and share repurchases.
Annual RBR and margin guidance: The company is affirming its annual RBR (Revenues Before Reimbursable expenses) and margin guidance for 2026, reflecting confidence in its growth strategy and strong pipeline.
AI Strategy and Market Opportunity: Huron is bullish on AI's potential impact, expecting it to significantly contribute to future growth, margin expansion, and shareholder value. The company has increased investments in AI capabilities and plans to deploy them across offerings and operations. The AI services market is projected to grow in double digits over the next several years.
Healthcare Segment Growth: The company anticipates continued growth in the Healthcare segment, driven by demand for performance improvement, revenue cycle managed services, financial advisory, and strategy offerings. The integration of AI capabilities is expected to enhance operational and technology expertise, positioning the segment for sustained growth.
Education Segment Outlook: Huron expects to leverage its strong market position in higher education to address challenges such as rising costs, funding declines, and regulatory scrutiny. The focus will be on delivering near-term financial improvements and modernizing operating models and academic offerings, with increasing use of AI.
Commercial Segment Growth: The Commercial segment is expected to grow due to demand for financial advisory, strategy offerings, and AI-enabled data-driven operating models. Investments in expanding offerings and industry expertise are anticipated to drive durable growth.
2026 Financial Guidance: The company projects RBR in the range of $1.78 billion to $1.86 billion, adjusted EBITDA margin between 14.5% and 15%, and adjusted non-GAAP EPS between $8.35 and $9.15 for 2026.
Capital Allocation Strategy: Huron plans to maintain a leverage ratio between 2x and 2.5x by the end of 2026, supported by disciplined capital allocation, including share repurchases and investments in growth initiatives.
Share Repurchase Program: Since December 31, 2022, the company has repurchased 5 million shares, representing 25% of its common stock outstanding. During the first quarter of 2026, the company used $155.5 million to repurchase approximately 1.1 million shares, representing 6.5% of its outstanding shares as of the beginning of the year. The company accelerated share repurchases during the first quarter due to a decline in share price and believes this reduction in share base, combined with earnings growth objectives, positions it well for future growth.
The earnings call highlights mixed signals: strong bookings, backlog, and growth in some segments, but negative free cash flow and rising debt. The Q&A revealed unclear responses on Healthcare engagement trends and AI growth specifics, suggesting potential concerns. Despite positive elements like record RBR growth and a strong buying environment in Education, uncertainties around Digital performance and leverage ratios suggest a neutral stock price movement. The market cap indicates moderate volatility, aligning with a neutral sentiment.
The earnings call summary indicates strong revenue growth and record performance in key segments, which is positive. However, the absence of information on dividends or share buybacks may dampen investor enthusiasm. The lack of detailed Q&A insights and unclear management responses suggest uncertainty, leading to a neutral sentiment. Given the company's market cap, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.
The earnings call presents strong financial performance with increased revenue, net income, and adjusted EBITDA. The guidance is optimistic, with anticipated growth across segments and strategic acquisitions. The Q&A section reveals positive sentiment from analysts, highlighting strong demand and effective management strategies. Although management avoided specific guidance for 2026, the overall outlook remains positive. Given the company's market cap, a positive stock price movement of 2% to 8% is likely over the next two weeks.
The earnings call highlights strong financial performance across segments, reaffirmed guidance, and record sales conversions, which are positive indicators. The Q&A session reveals improved visibility and confidence in overcoming temporary delays, though some responses lacked specific data. The market cap suggests moderate sensitivity to news. Overall, the combination of strong results, strategic acquisitions, and positive guidance adjustments suggests a positive stock price movement, likely in the range of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.